The presence of proteinaceous inclusions composed of abnormal filamentous assemblies within neurons and glia characterises most neurodegenerative diseases. Alpha-synuclein filaments define a group of neurodegenerative diseases termed synucleinopathies, the most prevalent being Parkinson’s disease. Understanding how alpha-synuclein aggregates and the cellular processes that influence alpha-synuclein accumulation is crucial to understanding synucleinopathies.
I am a postdoctoral researcher with an expertise in alpha-synuclein aggregation; I obtained my PhD in 2017 from the University of Cambridge with Prof. Michel Goedert. Now, as part of the Alzheimer’s Research UK Oxford Drug Discovery Institute and in collaboration with the Department of Physiology, Anatomy and Genetics, I am designing drug screening assays for potential targets in Parkinson’s disease.